TO THE EDITORWe read with great interest and a bit of surprise the article by Tonus et al. We would share herein our comments about it. The specificity of the fecal tumor M2 pyruvate kinase 0VI2-PK） reported by Tonus...TO THE EDITORWe read with great interest and a bit of surprise the article by Tonus et al. We would share herein our comments about it. The specificity of the fecal tumor M2 pyruvate kinase 0VI2-PK） reported by Tonus et al for diagnosing colorectal cancer （CRC） is 93%. This is considerably higher than in any of the previously published studies. In our work, the maximum specificity of fecal M2- PK is 78% （Table 1）. There is a vast difference of 15% between the previous studies and the current study of Tonus et al, which is difficult to explain. We are skeptical about such a high specificity reported by the authors.展开更多
文摘TO THE EDITORWe read with great interest and a bit of surprise the article by Tonus et al. We would share herein our comments about it. The specificity of the fecal tumor M2 pyruvate kinase 0VI2-PK） reported by Tonus et al for diagnosing colorectal cancer （CRC） is 93%. This is considerably higher than in any of the previously published studies. In our work, the maximum specificity of fecal M2- PK is 78% （Table 1）. There is a vast difference of 15% between the previous studies and the current study of Tonus et al, which is difficult to explain. We are skeptical about such a high specificity reported by the authors.
